Clinical Trials
25 trialsNCT07038343 2026-05-13
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Avenzo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06457503 2026-04-06
TRANSPARENT
Coherus Oncology, Inc.
Phase 4 Recruiting
NCT05261750 2026-02-25
Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer
PT. Prodia Stem Cell Indonesia
Phase 1/2 Active not recruiting
NCT05239143 2026-02-09
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
Poseida Therapeutics, Inc.
Phase 1 Active not recruiting
NCT05983432 2026-01-29
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
SystImmune Inc.
Phase 1 Recruiting
NCT05070247 2026-01-22
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
Phase 1/2 Terminated
NCT05544929 2026-01-06
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
Phase 1 Active not recruiting
NCT03144661 2025-10-21
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Incyte Corporation
Phase 1 Terminated
NCT05592626 2025-07-09
START-001
Marengo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06892431 2025-03-25
JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer
Shanghai JMT-Bio Inc.
Phase 2 Not yet recruiting
NCT03924986 2025-01-31
RATIONALE-309
BeiGene
Phase 3 Completed
NCT03769467 2024-11-14
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
Atara Biotherapeutics
Phase 1/2 Terminated
NCT06614686 2024-09-26
U87 CAR-T in Patients With Advanced Head and Neck Tumors
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1 Recruiting
NCT03682055 2023-08-15
Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)
Cullinan Therapeutics Inc.
Phase 1/2 Terminated
NCT02611960 2023-07-13
Keynote-122
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02578641 2023-06-28
VANCE
Tessa Therapeutics
Phase 3 Completed
NCT03517488 2022-12-01
DUET-2
Xencor, Inc.
Phase 1 Completed
NCT02605967 2022-02-10
Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
Novartis
Phase 2 Completed
NCT05198531 2022-01-21
To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Unknown
NCT02269943 2018-12-12
Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma
Celgene
Phase 2 Completed
NCT00439426 2016-11-02
A Study of Xeloda (Capecitabine) in Combination With XELOX (Oxaliplatin) in Patients With Metastatic Nasopharyngeal Cancer.
Hoffmann-La Roche
Phase 2 Completed
NCT02608073 2016-03-02
A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT00565448 2015-07-30
Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents
Sanofi
Phase 2 Completed
NCT00436293 2010-11-17
Taxotere + Cisplatin in Nasopharyngeal Carcinoma
Sanofi
Phase 2 Completed
NCT00436800 2009-09-18
Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma
Sanofi
Phase 2 Completed